About Serine/threonine/tyrosine-interacting-like protein 2
Serine/threonine/tyrosine-interacting-like protein 2 (STYXL2) is a protein
from Homo sapiens identified by UniProt accession
Q5VZP5, 1158 residues long.
MolForge cross-references it against 0 known binders and
13 disease associations.
Target properties
| Protein name | Serine/threonine/tyrosine-interacting-like protein 2 |
|---|
| UniProt accession | Q5VZP5 |
|---|
| Gene | STYXL2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1158 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (13)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.08
- immunodeficiency 75 · score 0.03
- Kimura disease · score 0.03
- Barrett's esophagus · score 0.03
- breast carcinoma · score 0.03
- leukocyte count · score 0.02
- esophageal adenocarcinoma · score 0.02
- Colon Sessile Serrated Adenoma/Polyp · score 0.02
- colorectal cancer · score 0.01
- oral squamous cell carcinoma · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q5VZP5-F1 | alphafold | PREDICTED | 54.96 | — |
Amino-acid sequence (1158 residues)
MATRKDTEEE QVVPSEEDEA NVRAVQAHYL RSPSPSQYSM VSDAETESIF MEPIHLSSAI AAKQIINEEL KPPGVRADAE CPGMLESAEQ LLVEDLYNRV REKMDDTSLY NTPCVLDLQR ALVQDRQEAP WNEVDEVWPN VFIAEKSVAV NKGRLKRLGI THILNAAHGT GVYTGPEFYT GLEIQYLGVE VDDFPEVDIS QHFRKASEFL DEALLTYRGK VLVSSEMGIS RSAVLVVAYL MIFHNMAILE ALMTVRKKRA IYPNEGFLKQ LRELNEKLME EREEDYGREG GSAEAEEGEG TGSMLGARVH ALTVEEEDDS ASHLSGSSLG KATQASKPLT LIDEEEEEKL YEQWKKGQGL LSDKVPQDGG GWRSASSGQG GEELEDEDVE RIIQEWQSRN ERYQAEGYRR WGREEEKEEE SDAGSSVGRR RRTLSESSAW ESVSSHDIWV LKQQLELNRP DHGRRRRADS MSSESTWDAW NERLLEIEKE ASRRYHAKSK REEAADRSSE AGSRVREDDE DSVGSEASSF YNFCSRNKDK LTALERWKIK RIQFGFHKKD LGAGDSSGEP GAEEAVGEKN PSDVSLTAYQ AWKLKHQKKV GSENKEEVVE LSKGEDSALA KKRQRRLELL ERSRQTLEES QSMASWEADS STASGSIPLS AFWSADPSVS ADGDTTSVLS TQSHRSHLSQ AASNIAGCST SNPTTPLPNL PVGPGDTISI ASIQNWIANV VSETLAQKQN EMLLLSRSPS VASMKAVPAA SCLGDDQVSM LSGHSSSSLG GCLLPQSQAR PSSDMQSVLS CNTTLSSPAE SCRSKVRGTS KPIFSLFADN VDLKELGRKE KEMQMELREK MSEYKMEKLA SDNKRSSLFK KKKVKEDEDD GVGDGDEDTD SAIGSFRYSS RSNSQKPETD TCSSLAVCDH YASGSRVGKE MDSSINKWLS GLRTEEKPPF QSDWSGSSRG KYTRSSLLRE TESKSSSYKF SKSQSEEQDT SSYHEANGNS VRSTSRFSSS STREGREMHK FSRSTYNETS SSREESPEPY FFRRTPESSE REESPEPQRP NWARSRDWED VEESSKSDFS EFGAKRKFTQ SFMRSEEEGE KERTENREEG RFASGRRSQY RRSTDREEEE EMDDEAIIAA WRRRQEETRT KLQKRRED
Explore Serine/threonine/tyrosine-interacting-like protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets